Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: One-year results

Retina

Volumn 30, Issue 5, 2010, Pages 739-747

  Scupola, Andrea ^a   Tiberti, Alessandra C ^a   Sasso, Paola ^a   Savastano, Maria C ^a   Mastrocola, Alessandra ^a   Marangoni, Dario ^a   Minnella, Angelo M ^a   Falsini, Benedetto ^a   Balestrazzi, Emilio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti VEGF; Bevacizumab; MP 1 microperimetry; Myopic neovascularization

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ANTERIOR EYE CHAMBER INFLAMMATION; ARTICLE; CENTRAL SCOTOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; MICROPERIMETRY; MYOPIC CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERIMETRY; REPEATED DRUG DOSE; RETINA DETACHMENT; SIDE EFFECT; SINGLE DRUG DOSE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FIXATION, OCULAR; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULA LUTEA; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PERIMETRY; PROSPECTIVE STUDIES; RETREATMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELDS; VITREOUS BODY;

EID: 77952273753     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c59725     Document Type: Article

References (28)

1. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
2. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelialderived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28:1308-1313.
3. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study) : results of a phase 1 doseescalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
4. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006;26:1093-1094.
5. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006;26:960-963. (Pubitemid 44547453)
6. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160.
7. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165. (Pubitemid 46202863)
8. Rosenfeld PJ. Intravitreal Avastin for choroidal neovascularization in pathological myopia: the controversy continues. Br J Ophthalmol 2007;91:128-130.
9. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-96.
10. Ray R, Stinnett SS, Jaffe GJ. Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol 2005;139:18-29.
11. Polito A, Napolitano MC, Bandello F, Chiodini RG. The role of optical coherence tomography (OCT) in the diagnosis and management of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration. Ann Acad Med Singapore 2006;35:420-424.
12. Fujii GY, de Juan E Jr, Sunness J, Humayun MS, Pieramici DJ, Chang TS. Patient selection for macular translocation surgery using the scanning laser ophthalmoscope. Ophthalmology 2002;109:1737-1744.
13. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004; 24: S3-S19.
14. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108:841-852.
15. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-673.
16. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-154.
17. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
18. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009 Jan 16 [Epub ahead of print].
19. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
20. Midena E. Microperimetry. Arch Soc Esp Oftalmol 2006;81:183-186.
21. Mori F, Ishiko S, Kitaya N, et al. Scotoma and fixation patterns using scanning laser ophthalmoscope microperimetry in patients with macular dystrophy. Am J Ophthalmol 2001;132:897-902.
22. Rohrschneider K, Gluck R, Becker M, et al. Scanning laser fundus perimetry before laser photocoagulation of well defined choroidal neovascularisation. Br J Ophthalmol 1997;81:568-573.
23. Sunness JS, Applegate CA, Haselwood D, Rubin GS. Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology 1996;103:1458-1466.
24. Sjaarda RN, Frank DA, Glaser BM, Thompson JT, Murphy RP. Assessment of vision in idiopathic macular holes with macular microperimetry using the scanning laser ophthalmoscope. Ophthalmology 1993;100:1513-1518.
25. Varano M, Scassa C, Capaldo N, Sciamanna M, Parisi V. Development of macular pseudoholes: a 36-month period of follow-up. Retina 2002;22:435-442.
26. Yodoi Y, Tsujikawa A, Nakanishi H, et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009;147:816-824.
27. Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007;91:827-831.
28. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009;148:396-408.